Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Total Non-Current Liabilities (2017 - 2023)

Historic Total Non-Current Liabilities for Vistagen Therapeutics (VTGN) over the last 10 years, with Q3 2023 value amounting to $3.6 million.

  • Vistagen Therapeutics' Total Non-Current Liabilities fell 2791.76% to $3.6 million in Q3 2023 from the same period last year, while for Sep 2023 it was $3.6 million, marking a year-over-year decrease of 2791.76%. This contributed to the annual value of $4.4 million for FY2023, which is 669.71% up from last year.
  • Latest data reveals that Vistagen Therapeutics reported Total Non-Current Liabilities of $3.6 million as of Q3 2023, which was down 2791.76% from $4.1 million recorded in Q2 2023.
  • Vistagen Therapeutics' 5-year Total Non-Current Liabilities high stood at $12.7 million for Q3 2020, and its period low was $3.6 million during Q3 2023.
  • For the 5-year period, Vistagen Therapeutics' Total Non-Current Liabilities averaged around $7.6 million, with its median value being $8.0 million (2019).
  • As far as peak fluctuations go, Vistagen Therapeutics' Total Non-Current Liabilities surged by 15338.67% in 2019, and later tumbled by 6883.24% in 2022.
  • Vistagen Therapeutics' Total Non-Current Liabilities (Quarter) stood at $8.5 million in 2019, then soared by 47.01% to $12.5 million in 2020, then crashed by 66.85% to $4.1 million in 2021, then rose by 14.73% to $4.7 million in 2022, then dropped by 23.3% to $3.6 million in 2023.
  • Its Total Non-Current Liabilities was $3.6 million in Q3 2023, compared to $4.1 million in Q2 2023 and $4.4 million in Q1 2023.